Curcumin - Revision history

Lazy at 08:19, 18 January 2025

2025-01-18T08:19:56Z

← Older revision		Revision as of 01:19, 18 January 2025
Line 43:		Line 43:
	* [Curcumin and Cancer (PDQ®) - NCI](https://www.cancer.gov/about-cancer/treatment/cam/patient/curcumin-pdq)		* [Curcumin and Cancer (PDQ®) - NCI](https://www.cancer.gov/about-cancer/treatment/cam/patient/curcumin-pdq)
	\|toxicity_explanation=Curcumin, the active ingredient in turmeric, is generally well-tolerated with minimal side effects. As a dietary supplement, it has the lowest toxicity rating. This number (1) represents minimal toxicity. Remember, however, that while curcumin is showing some promising results in laboratory studies, it is not an FDA-approved cancer treatment and is currently under investigation.		\|toxicity_explanation=Curcumin, the active ingredient in turmeric, is generally well-tolerated with minimal side effects. As a dietary supplement, it has the lowest toxicity rating. This number (1) represents minimal toxicity. Remember, however, that while curcumin is showing some promising results in laboratory studies, it is not an FDA-approved cancer treatment and is currently under investigation.
	}}		\|overview=Curcumin, derived from turmeric, is not FDA-approved for cancer treatment but is being studied for its potential anti-cancer properties and symptom management in various conditions. While generally well-tolerated and exhibiting promising effects in laboratory studies, particularly in glioblastoma and dermatitis management, its clinical utility remains under investigation with limitations in bioavailability and a focus on early treatment contexts.}}

69.163.248.232: Updated category= to treatment_category= in TreatmentInfo template

2024-11-12T18:29:44Z

Updated category= to treatment_category= in TreatmentInfo template

← Older revision		Revision as of 11:29, 12 November 2024
Line 12:		Line 12:
	\|toxicity_level=1		\|toxicity_level=1
	\|notes=Curcumin, derived from turmeric, exhibits multiple anti-cancer properties in laboratory studies, including inhibition of tyrosine kinase signaling, angiogenesis, and promotion of apoptosis via NF-kB inhibition. Its bioavailability is limited but can be enhanced with piperine. Clinical evidence of its effectiveness includes reducing dermatitis in breast cancer radiotherapy and decreasing polyp size and number in colon conditions. While promising in laboratory settings for its anti-cancer potential, further research is required to fully understand its clinical efficacy and optimal use in cancer treatment.		\|notes=Curcumin, derived from turmeric, exhibits multiple anti-cancer properties in laboratory studies, including inhibition of tyrosine kinase signaling, angiogenesis, and promotion of apoptosis via NF-kB inhibition. Its bioavailability is limited but can be enhanced with piperine. Clinical evidence of its effectiveness includes reducing dermatitis in breast cancer radiotherapy and decreasing polyp size and number in colon conditions. While promising in laboratory settings for its anti-cancer potential, further research is required to fully understand its clinical efficacy and optimal use in cancer treatment.
	\|~~category~~=Nutraceuticals		\|treatment_category=Nutraceuticals
	\|book_text=Curcumin		\|book_text=Curcumin

Lazy at 20:55, 12 April 2024

2024-04-12T20:55:33Z

← Older revision		Revision as of 13:55, 12 April 2024
Line 4:		Line 4:
	\|used_for=Investigational use in cancer treatment and prevention; also used for symptom management like dermatitis from radiotherapy		\|used_for=Investigational use in cancer treatment and prevention; also used for symptom management like dermatitis from radiotherapy
	\|clinical_trial_phase=Preclinical studies and early clinical trials		\|clinical_trial_phase=Preclinical studies and early clinical trials
			\|clinical_trial_explanation=Curcumin is being studied in preclinical and early clinical trials to assess its potential as an anti-cancer agent. While not directly focusing on survival metrics like OS or PFS, these studies explore its biochemical mechanisms that could influence cancer cell behavior and patient symptoms.
	\|common_side_effects=Generally well-tolerated; bioavailability issues are noted, but can be improved with piperine		\|common_side_effects=Generally well-tolerated; bioavailability issues are noted, but can be improved with piperine
	\|OS_with=Not applicable; studies focus on cellular and symptom management rather than direct survival outcomes		\|OS_with=Not applicable; studies focus on cellular and symptom management rather than direct survival outcomes
	\|PFS_with=Not applicable; research has not extensively measured progression-free survival in cancer patients		\|PFS_with=Not applicable; research has not extensively measured progression-free survival in cancer patients
	\|usefulness_rating=3		\|usefulness_rating=3
			\|usefulness_explanation=Curcumin has demonstrated potential in laboratory studies for its anti-cancer properties including inhibition of key signaling pathways, promotion of cancer cell apoptosis, and reduction of inflammation and angiogenesis. Its clinical utility in cancer care, particularly in glioblastoma, remains under investigation with early evidence suggesting benefits in symptom management and possibly enhancing the effects of conventional treatments.
	\|toxicity_level=1		\|toxicity_level=1
	\|notes=Curcumin, derived from turmeric, exhibits multiple anti-cancer properties in laboratory studies, including inhibition of tyrosine kinase signaling, angiogenesis, and promotion of apoptosis via NF-kB inhibition. Its bioavailability is limited but can be enhanced with piperine. Clinical evidence of its effectiveness includes reducing dermatitis in breast cancer radiotherapy and decreasing polyp size and number in colon conditions. While promising in laboratory settings for its anti-cancer potential, further research is required to fully understand its clinical efficacy and optimal use in cancer treatment.		\|notes=Curcumin, derived from turmeric, exhibits multiple anti-cancer properties in laboratory studies, including inhibition of tyrosine kinase signaling, angiogenesis, and promotion of apoptosis via NF-kB inhibition. Its bioavailability is limited but can be enhanced with piperine. Clinical evidence of its effectiveness includes reducing dermatitis in breast cancer radiotherapy and decreasing polyp size and number in colon conditions. While promising in laboratory settings for its anti-cancer potential, further research is required to fully understand its clinical efficacy and optimal use in cancer treatment.
Line 36:		Line 38:
	For all patients there was a decrease in polyp size and number, which was statistically		For all patients there was a decrease in polyp size and number, which was statistically
	significant.		significant.
	\|links=		\|links=* [ClinicalTrials.gov study of Liposomal Curcumin in combination with RT and TMZ](https://clinicaltrials.gov/ct2/show/NCT03552471)
			* [Systematic review of clinical effects of curcumin in cancer therapy](https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-5760-2)
			* [Antitumor Activity of Curcumin in Glioblastoma](https://www.mdpi.com/1422-0067/21/24/9435)
			* [Curcumin and Cancer (PDQ®) - NCI](https://www.cancer.gov/about-cancer/treatment/cam/patient/curcumin-pdq)
	\|toxicity_explanation=Curcumin, the active ingredient in turmeric, is generally well-tolerated with minimal side effects. As a dietary supplement, it has the lowest toxicity rating. This number (1) represents minimal toxicity. Remember, however, that while curcumin is showing some promising results in laboratory studies, it is not an FDA-approved cancer treatment and is currently under investigation.		\|toxicity_explanation=Curcumin, the active ingredient in turmeric, is generally well-tolerated with minimal side effects. As a dietary supplement, it has the lowest toxicity rating. This number (1) represents minimal toxicity. Remember, however, that while curcumin is showing some promising results in laboratory studies, it is not an FDA-approved cancer treatment and is currently under investigation.
	}}		}}

Lazy at 18:08, 27 March 2024

2024-03-27T18:08:49Z

← Older revision		Revision as of 11:08, 27 March 2024
Line 10:		Line 10:
	\|toxicity_level=1		\|toxicity_level=1
	\|notes=Curcumin, derived from turmeric, exhibits multiple anti-cancer properties in laboratory studies, including inhibition of tyrosine kinase signaling, angiogenesis, and promotion of apoptosis via NF-kB inhibition. Its bioavailability is limited but can be enhanced with piperine. Clinical evidence of its effectiveness includes reducing dermatitis in breast cancer radiotherapy and decreasing polyp size and number in colon conditions. While promising in laboratory settings for its anti-cancer potential, further research is required to fully understand its clinical efficacy and optimal use in cancer treatment.		\|notes=Curcumin, derived from turmeric, exhibits multiple anti-cancer properties in laboratory studies, including inhibition of tyrosine kinase signaling, angiogenesis, and promotion of apoptosis via NF-kB inhibition. Its bioavailability is limited but can be enhanced with piperine. Clinical evidence of its effectiveness includes reducing dermatitis in breast cancer radiotherapy and decreasing polyp size and number in colon conditions. While promising in laboratory settings for its anti-cancer potential, further research is required to fully understand its clinical efficacy and optimal use in cancer treatment.
	\|category=Nutraceuticals ~~and Herbals~~		\|category=Nutraceuticals
	\|book_text=Curcumin		\|book_text=Curcumin

Lazy at 16:54, 27 March 2024

2024-03-27T16:54:39Z

← Older revision		Revision as of 09:54, 27 March 2024
Line 37:		Line 37:
	significant.		significant.
	\|links=		\|links=
			\|toxicity_explanation=Curcumin, the active ingredient in turmeric, is generally well-tolerated with minimal side effects. As a dietary supplement, it has the lowest toxicity rating. This number (1) represents minimal toxicity. Remember, however, that while curcumin is showing some promising results in laboratory studies, it is not an FDA-approved cancer treatment and is currently under investigation.
	}}		}}

Lazy at 07:09, 26 March 2024

2024-03-26T07:09:14Z

← Older revision		Revision as of 00:09, 26 March 2024
Line 11:		Line 11:
	\|notes=Curcumin, derived from turmeric, exhibits multiple anti-cancer properties in laboratory studies, including inhibition of tyrosine kinase signaling, angiogenesis, and promotion of apoptosis via NF-kB inhibition. Its bioavailability is limited but can be enhanced with piperine. Clinical evidence of its effectiveness includes reducing dermatitis in breast cancer radiotherapy and decreasing polyp size and number in colon conditions. While promising in laboratory settings for its anti-cancer potential, further research is required to fully understand its clinical efficacy and optimal use in cancer treatment.		\|notes=Curcumin, derived from turmeric, exhibits multiple anti-cancer properties in laboratory studies, including inhibition of tyrosine kinase signaling, angiogenesis, and promotion of apoptosis via NF-kB inhibition. Its bioavailability is limited but can be enhanced with piperine. Clinical evidence of its effectiveness includes reducing dermatitis in breast cancer radiotherapy and decreasing polyp size and number in colon conditions. While promising in laboratory settings for its anti-cancer potential, further research is required to fully understand its clinical efficacy and optimal use in cancer treatment.
	\|category=Nutraceuticals and Herbals		\|category=Nutraceuticals and Herbals
	\|~~original_text~~=Curcumin		\|book_text=Curcumin

	This is an ingredient in the Indian cooking spice, turmeric. It has been shown to inhibit		This is an ingredient in the Indian cooking spice, turmeric. It has been shown to inhibit

Lazy at 07:08, 26 March 2024

2024-03-26T07:08:16Z

@@ Line 8: / Line 8: @@
 |PFS_with=Not applicable; research has not extensively measured progression-free survival in cancer patients
 |usefulness_rating=3
 |notes=Curcumin, derived from turmeric, exhibits multiple anti-cancer properties in laboratory studies, including inhibition of tyrosine kinase signaling, angiogenesis, and promotion of apoptosis via NF-kB inhibition. Its bioavailability is limited but can be enhanced with piperine. Clinical evidence of its effectiveness includes reducing dermatitis in breast cancer radiotherapy and decreasing polyp size and number in colon conditions. While promising in laboratory settings for its anti-cancer potential, further research is required to fully understand its clinical efficacy and optimal use in cancer treatment.
 |category=Nutraceuticals and Herbals
 |links=
 }}

Lazy: Created page with "{{TreatmentInfo |drug_name=Curcumin |FDA_approval=No (Used as a dietary supplement; not FDA-approved for cancer treatment) |used_for=Investigational use in cancer treatment and prevention; also used for symptom management like dermatitis from radiotherapy |clinical_trial_phase=Preclinical studies and early clinical trials |common_side_effects=Generally well-tolerated; bioavailability issues are noted, but can be improved with piperine |OS_with=Not applicable; studies foc..."

2024-03-21T12:34:41Z

Created page with "{{TreatmentInfo |drug_name=Curcumin |FDA_approval=No (Used as a dietary supplement; not FDA-approved for cancer treatment) |used_for=Investigational use in cancer treatment and prevention; also used for symptom management like dermatitis from radiotherapy |clinical_trial_phase=Preclinical studies and early clinical trials |common_side_effects=Generally well-tolerated; bioavailability issues are noted, but can be improved with piperine |OS_with=Not applicable; studies foc..."

New page

{{TreatmentInfo
|drug_name=Curcumin
|FDA_approval=No (Used as a dietary supplement; not FDA-approved for cancer treatment)
|used_for=Investigational use in cancer treatment and prevention; also used for symptom management like dermatitis from radiotherapy
|clinical_trial_phase=Preclinical studies and early clinical trials
|common_side_effects=Generally well-tolerated; bioavailability issues are noted, but can be improved with piperine
|OS_with=Not applicable; studies focus on cellular and symptom management rather than direct survival outcomes
|PFS_with=Not applicable; research has not extensively measured progression-free survival in cancer patients
|usefulness_rating=3
|notes=Curcumin, derived from turmeric, exhibits multiple anti-cancer properties in laboratory studies, including inhibition of tyrosine kinase signaling, angiogenesis, and promotion of apoptosis via NF-kB inhibition. Its bioavailability is limited but can be enhanced with piperine. Clinical evidence of its effectiveness includes reducing dermatitis in breast cancer radiotherapy and decreasing polyp size and number in colon conditions. While promising in laboratory settings for its anti-cancer potential, further research is required to fully understand its clinical efficacy and optimal use in cancer treatment.
|category=Nutraceuticals and Herbals
|links=
}}